Galmed Pharmaceuticals (GLMD) Current Deferred Revenue (2016 - 2018)
Galmed Pharmaceuticals (GLMD) posted quarterly Current Deferred Revenue of $538000.0 for Q4 2017, down 50.82% year-over-year from $1.1 million in Q4 2016, and down 50.41% quarter-over-quarter from $1.1 million in Q2 2017.
Galmed Pharmaceuticals (GLMD) Current Deferred Revenue (2016 - 2018) Analysis & Trends
Galmed Pharmaceuticals' Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $538000.0 for Q4 2017.
- In Q4 2017, Current Deferred Revenue fell 50.82% year-over-year to $538000.0; the TTM figure through Dec 2017 stood at $538000.0 (down 50.82% YoY), while the FY2017 annual figure was $538000.0, down 50.82% from the prior year.
- Current Deferred Revenue for Q4 2017 stood at $538000.0, down from $1.1 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $1.1 million in Q4 2016, with the low at $538000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 270,000.00 |
| Dec 31, 2017 | 538,000.00 |
| Jun 30, 2017 | 1.09 Mn |
| Dec 31, 2016 | 1.09 Mn |